FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Eisai/Biogen Report Promising Alzheimers Data

[ Price : $8.95]

Eisai and Biogen report new data from a lecanemab Alzheimers Phase 3 trial that suggest treated patients with early Alzheimers dis...

Ferrings Fecal Microbiota Product Approved for C.diff

[ Price : $8.95]

FDA approves Ferring Pharmaceuticals Rebyota (fecal microbiota) for preventing recurrence of Clostridioides difficile infection in...

Ex-BD Official Seeks DoJ Referral Against Company

[ Price : $8.95]

A former Becton Dickinson safety official petitions FDA to refer the company to the U.S. Justice Department for allegedly violatin...

Objectionable Conditions at Arbor Eyecare

[ Price : $8.95]

FDA warns Arbor Centers for EyeCare about objectionable conditions in its conduct of two clinical investigations.

Guide on Fecal Microbiota Enforcement Policy

[ Price : $8.95]

Federal Register notice: FDA makes available a final guidance entitled Enforcement Policy Regarding Investigational New Drug Requi...

CDER Hearing Delay on NDA is Unfounded: Lexicon

[ Price : $8.95]

Lexicon asks that its NDA for sotagliflozin be approved to treat Type 1 diabetes or that a hearing be held to resolve issues of fa...

Suggestions to Improve OTC Drug Draft Reg

[ Price : $8.95]

Five stakeholders recommend changes to an FDA proposed rule on nonprescription drug products with an additional condition for nonp...

Roche Withdraws Tecentriq Bladder Cancer Indication

[ Price : $8.95]

Roche withdraws a Tecentriq (atezolizumab) accelerated approval indication for treating certain adults with locally advanced or me...

Mylan Requests Sulfamylon Withdrawal

[ Price : $8.95]

Federal Register notice: FDA withdraws the approval of Mylans Sulfamylon (mafenide acetate, USP) powder for 5% topical solution af...

Skinny Labels Lead to Earlier Competition: Study

[ Price : $8.95]

Researchers document the Medicare savings associated with skinny label biosimilars.